Previous close | 0.0800 |
Open | 0.0500 |
Bid | 0.0500 |
Ask | 0.1000 |
Strike | 17.50 |
Expiry date | 2024-05-17 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 41 |
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders are probably feeling a little disappointed, since its shares fell...
Beam Therapeutics (BEAM) reports mixed first-quarter results. The company remains focused on pipeline development.
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2024 Global Healthcare Conference on Wednesday, May 15, 2024, at 1:35 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at www.bea